undamentalytics Newsletter
Sign in

Crispr Therapeutics AG (CRSP) stock

Add to watchlist

Add holding +

NASDAQ: CRSP Nasdaq Biotechnology Next results ~February 11, 2027

D Fundamentals grade

Crispr Therapeutics AG is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$25

Growth cash-flow model

Base case. Range ~$20–$30. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Crispr Therapeutics AG valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 30 sales by directors and officers, last 12 monthsInsider trades
  • Funds228 adding, 187 cuttingOf 41 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Crispr Therapeutics AG files

10-Q filed November 2: Crispr Therapeutics AG

Model value −8.4%

Crispr Therapeutics AG reported revenue of $25m for the twelve months to September 2026, down 34.3% on a year earlier. That decline eased from the steeper 64.8% drop recorded a quarter earlier. Margins moved the other way, however: free-cash-flow margin fell to -1496.6% from -790.7% a year earlier, while the operating margin narrowed to -2114.8% from -1498.3%. Existing holders also face further dilution, with the diluted share count up 10.0% over the year. Taken together, these shifts have pulled our model value down from $27.25 to $24.96 a share. That figure sits well below the current share price of $49.79, underlining the gap between the market's valuation and our own.

Source: 10-Q filed November 2, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Crispr Therapeutics AG stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $13m, down 64.8% on a year earlier, a smaller fall than the 89.1% decline a quarter earlier. That puts it 111 of 128 for growth among the biotechnology companies we cover. Free-cash-flow margin fell to -2772.7% from -855.6% a year earlier. Operating margin narrowed to -3990.0% from -1451.9%. The diluted share count is up 10.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 5 financial-health checks. Our growth cash-flow model value is $27.25 a share.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 11, 2027 (estimated)

Crispr Therapeutics AG's trailing-twelve-month revenue fell 34.3% year on year, with a free-cash-flow margin of -1496.6%. Where it stands out: change in growth rate of +30.5pp ranks 33 of 172 biotechnology companies we cover. Where it lags: stock pay as % of revenue of 276.8% ranks 156 of 179 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 24.3% while net income grew 6.6%: a 31pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Crispr Therapeutics AG's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 34.3% over the last 12 months.
  • Loss-making. Operating margin is -2114.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 616.5 points on a year ago.
  • Burning cash. Free cash flow was -1496.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 276.8% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 10.0% in a year.

Latest results: FY2026 Q3

Filed November 2, 2026
Earnings per share
-$1.15 against an average estimate of -$1.06: missed by 8.5%
Revenue
$13m, up 1325.1% on a year earlier
Next report
November 2, 2026; average EPS estimate -$1.16

Crispr Therapeutics AG's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.8%
  • 1 week+2.0%
  • 1 month-9.8%
  • This year-4.7%
  • 1 year-21.9%
  • 5 years-48.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$25.2M
Operating margin
-2114.8%
Net margin
-1812.1%
EPS (TTM, diluted)
$-4.74

Growth

Revenue growth
−34.3%
Change in growth rate
+30.5 pts
Share count change
+10.0%

Cash

Free cash flow (TTM)
-$377M
FCF margin
-1496.6%
Stock pay % of revenue
276.8%

Earnings

Last results
November 2, 2026
Next results (est.)
February 11, 2027

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Insider trade
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Crispr Therapeutics AG valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Crispr Therapeutics AG as an operating company, with every model that fits that kind of business. Cost of equity 10.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.32 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$25 ~$20–$30 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.9 ~$5.0–$19 Left out: out of range vs price (0.10x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$2.5 ~$0.5–$2.5 Left out: out of range vs price (0.05x)
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$25 ~$20–$30 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Crispr Therapeutics AG with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$20.26$23.48$28.57$60.91$153.11$75.78$40.65$62.60$39.36$52.44$49.99
Market value$248m$941m$1.4bn$3.5bn$10.1bn$6.1bn$3.2bn$5.0bn$3.3bn$4.7bn$4.8bn
+ Net debt (− = net cash)−$316m−$240m−$457m−$944m−$1.2bn−$923m−$212m−$389m−$298m−$348m$408m
Enterprise value−$67m$701m$914m$2.5bn$8.9bn$5.2bn$2.9bn$4.6bn$3.0bn$4.4bn$5.2bn
Multiples
Price / sales 48.1x22.9xn/m12.0xn/m6.7xn/m13.4x89.0xn/m191.0x
Price / earnings ———51.9x—16.1x—————
Price / free cash flow ———69.4x—13.3x—————
EV / EBITDA ———49.0x—13.2x—————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

10 /100

Weak moat

How hard Crispr Therapeutics AG's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -17.4% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -311.9%; its worst year was -4877.7%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -227.7% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 27.0% over five years; stock-based pay has been a median 82.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.45 +31% $40m +1052%
Next −$3.55 +20% $154m +281%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −8.9% on 90 days ago. In the last 30 days, 0 analysts raised Crispr Therapeutics AG's forecast and 1 cut it.

Consensus EPS forecast Crispr Therapeutics AG, last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.88 Current fiscal year, 60 days ago: −$4.45 Current fiscal year, 30 days ago: −$4.45 Current fiscal year, 7 days ago: −$4.45 Current fiscal year, Now: −$4.45 −$4.45 Next fiscal year, 90 days ago: −$3.89 Next fiscal year, 60 days ago: −$3.50 Next fiscal year, 30 days ago: −$3.50 Next fiscal year, 7 days ago: −$3.55 Next fiscal year, Now: −$3.55 −$3.55

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.88−$3.89
60 days ago −$4.45−$3.50
30 days ago −$4.45−$3.50
7 days ago −$4.45−$3.55
Now −$4.45−$3.55

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$1.06 −$1.15 −8.5%
Jun 2026 −$1.18 −$0.94 +20.6%
Mar 2026 −$1.23 −$1.28 −3.7%
Dec 2025 −$1.23 −$1.37 −11.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

23 analysts, Nov 2026
Buy1357%
Hold1043%
Sell00%

Monthly trend

  1. Nov 2026491023
  2. Oct 202658922
  3. Sep 202658922

Counts of recommendations published by analysts covering Crispr Therapeutics AG, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
19.5%
of tradable shares
Days to cover
9.18
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
80%
of shares
Held by insiders
6.0%
of shares

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −21.9%

$63.99 on October 31, 2025 to $49.99

ThenNowEffect
Revenue (last 12 months) $38m $13m −64.8%
P/S multiple 144.5x n/m +144.9%
Share count 86m 95m −9.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −2.0%

$50.99 on November 3, 2023 to $49.99

ThenNowEffect
Revenue (last 12 months) $170m $13m −92.1%
P/S multiple 23.5x n/m +1403.4%
Share count 79m 95m −17.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CRSP−51%−46%+54%−37%+33%−5%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CRSP33%50%42%50%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CRSP−67%−53%−43%−57%−41%−28%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 19, 2016: 85% from January 14, 2021 to April 8, 2025. Getting back needed a 572% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$44.34 – $61.97
From 52-week high
−19.3%
vs 50-day average
−7.4%
vs 200-day average
−5.4%
Volatility (1 year)
58%
Beta vs S&P 500
1.91

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 4 down
typical move ±5.3%
After a week
8 up, 3 down
typical move ±7.9%
After a month
7 up, 4 down
typical move ±5.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 +10.6% +3.3% +11.5% +18.4%
May 4, 2026 +1.5% +0.4% +4.6% +0.9%
February 12, 2026 +9.8% −1.5% +10.6% +0.2%
November 10, 2025 +0.2% +1.8% +0.4% +4.5%
August 4, 2025 −0.9% +1.0% −1.2% −5.5%
May 6, 2025 −9.0% −0.4% −1.1% +2.5%
February 11, 2025 +9.9% −0.2% +34.5% +6.5%
November 5, 2024 +0.3% +3.7% +0.3% −2.1%
August 5, 2024 −3.5% −2.0% −8.2% −11.9%
May 8, 2024 −3.6% +0.6% +2.6% +4.2%
February 21, 2024 +9.5% +2.2% +11.4% −5.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Crispr Therapeutics AG in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Crispr Therapeutics AG
$0 $100M $200M $300M $400M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $371.2M Revenue (TTM), FY24 Q1: $271.7M Revenue (TTM), FY24 Q2: $202.2M Revenue (TTM), FY24 Q3: $202.8M Revenue (TTM), FY24 Q4: $37.3M Revenue (TTM), FY25 Q1: $37.7M Revenue (TTM), FY25 Q2: $38.1M Revenue (TTM), FY25 Q3: $38.3M Revenue (TTM), FY25 Q4: $3.5M Revenue (TTM), FY26 Q1: $4.1M Revenue (TTM), FY26 Q2: $13.4M Revenue (TTM), FY26 Q3: $25.2M $25.2M

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $371.2M
FY24 Q1 $271.7M
FY24 Q2 $202.2M
FY24 Q3 $202.8M
FY24 Q4 $37.3M
FY25 Q1 $37.7M
FY25 Q2 $38.1M
FY25 Q3 $38.3M
FY25 Q4 $3.5M
FY26 Q1 $4.1M
FY26 Q2 $13.4M
FY26 Q3 $25.2M
Revenue growth, TTM YoY Crispr Therapeutics AG
-10000% 0% 10000% 20000% 30000% 40000% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 30885.5% Revenue growth, TTM YoY, FY24 Q1: 171.0% Revenue growth, TTM YoY, FY24 Q2: 18.9% Revenue growth, TTM YoY, FY24 Q3: 19.3% Revenue growth, TTM YoY, FY24 Q4: -89.9% Revenue growth, TTM YoY, FY25 Q1: -86.1% Revenue growth, TTM YoY, FY25 Q2: -81.2% Revenue growth, TTM YoY, FY25 Q3: -81.1% Revenue growth, TTM YoY, FY25 Q4: -90.6% Revenue growth, TTM YoY, FY26 Q1: -89.1% Revenue growth, TTM YoY, FY26 Q2: -64.8% Revenue growth, TTM YoY, FY26 Q3: -34.3% -34.3%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 30885.5%
FY24 Q1 171.0%
FY24 Q2 18.9%
FY24 Q3 19.3%
FY24 Q4 -89.9%
FY25 Q1 -86.1%
FY25 Q2 -81.2%
FY25 Q3 -81.1%
FY25 Q4 -90.6%
FY26 Q1 -89.1%
FY26 Q2 -64.8%
FY26 Q3 -34.3%
Operating margin (TTM) Crispr Therapeutics AG
-20000% -15000% -10000% -5000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -60.0% Operating margin (TTM), FY24 Q1: -109.9% Operating margin (TTM), FY24 Q2: -175.4% Operating margin (TTM), FY24 Q3: -163.9% Operating margin (TTM), FY24 Q4: -1250.4% Operating margin (TTM), FY25 Q1: -1259.2% Operating margin (TTM), FY25 Q2: -1451.9% Operating margin (TTM), FY25 Q3: -1498.3% Operating margin (TTM), FY25 Q4: -18933.6% Operating margin (TTM), FY26 Q1: -15754.2% Operating margin (TTM), FY26 Q2: -3990.0% Operating margin (TTM), FY26 Q3: -2114.8% -2114.8%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -60.0%
FY24 Q1 -109.9%
FY24 Q2 -175.4%
FY24 Q3 -163.9%
FY24 Q4 -1250.4%
FY25 Q1 -1259.2%
FY25 Q2 -1451.9%
FY25 Q3 -1498.3%
FY25 Q4 -18933.6%
FY26 Q1 -15754.2%
FY26 Q2 -3990.0%
FY26 Q3 -2114.8%
FCF margin (TTM) Crispr Therapeutics AG
-10000% -5000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -72.7% FCF margin (TTM), FY24 Q1: -61.3% FCF margin (TTM), FY24 Q2: -62.3% FCF margin (TTM), FY24 Q3: -94.3% FCF margin (TTM), FY24 Q4: -387.7% FCF margin (TTM), FY25 Q1: -817.1% FCF margin (TTM), FY25 Q2: -855.6% FCF margin (TTM), FY25 Q3: -790.7% FCF margin (TTM), FY25 Q4: -9855.5% FCF margin (TTM), FY26 Q1: -9777.6% FCF margin (TTM), FY26 Q2: -2772.7% FCF margin (TTM), FY26 Q3: -1496.6% -1496.6%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -72.7%
FY24 Q1 -61.3%
FY24 Q2 -62.3%
FY24 Q3 -94.3%
FY24 Q4 -387.7%
FY25 Q1 -817.1%
FY25 Q2 -855.6%
FY25 Q3 -790.7%
FY25 Q4 -9855.5%
FY26 Q1 -9777.6%
FY26 Q2 -2772.7%
FY26 Q3 -1496.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 0 5 41 3 290 1 915 1 371 37 4 25
EBITDA −26 −67 −62 −155 51 −345 391 −649 −203 −447 −645 −514
Operating income −26 −68 −65 −159 47 −354 374 −673 −223 −467 −665 −532
Net income −26 −23 −68 −165 67 −349 378 −650 −154 −366 −582 −456
Diluted EPS −$5.06 −$1.89 −$1.71 −$3.44 $1.17 −$5.29 $4.70 −$8.36 −$1.94 −$4.34 −$6.47 −$4.74
Growth (year on year)
Revenue — +>999% +693.9% −92.4% +>999% −99.8% +>999% −99.9% +>999% −89.9% −90.6% −34.3%
EBITDA — — — — — −770.8% — −265.8% — — — —
Operating income — — — — — −858.3% — −280.2% — — — —
Net income — — — — — −621.8% — −272.2% — — — —
Diluted EPS — — — — — −552.1% — −277.9% — — — —
Margins
EBITDA margin <−999% <−999% −150.3% <−999% 17.8% <−999% 42.8% <−999% −54.6% <−999% <−999% <−999%
Operating margin <−999% <−999% −157.7% <−999% 16.1% <−999% 40.8% <−999% −60.0% <−999% <−999% <−999%
Net margin <−999% −448.8% −166.7% <−999% 23.1% <−999% 41.3% <−999% −41.4% −981.5% <−999% <−999%
Free-cash-flow margin >999% <−999% −190.0% <−999% 17.3% <−999% 50.0% <−999% −72.7% −387.7% <−999% <−999%
Cash flow
Cash from operations 59 −53 −70 −96 57 −238 539 −496 −260 −143 −345 −375
Capital spending 1 3 8 3 7 18 82 37 9 2 1 2
Free cash flow 58 −56 −78 −99 50 −257 457 −533 −270 −145 −346 −377
Stock-based pay 4 11 19 35 44 66 102 98 81 87 72 70
Free cash flow after stock pay 55 −67 −97 −134 6 −323 355 −631 −351 −231 −418 −446
Balance sheet
Cash 156 316 240 457 944 1,169 923 212 389 298 348 192
Total debt 38 — 0 0 0 0 0 0 0 0 0 600
Net debt (negative = net cash) −118 −316 −240 −457 −944 −1,169 −923 −212 −389 −298 −348 408
Diluted shares 5m 12m 40m 48m 57m 66m 80m 78m 79m 84m 90m 96m
Returned to shareholders
Buybacks — — — 0 — — — — — — — —
Total returned — — — 0 — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 5 checks passed · September 30, 2026
What it owns · $2.6bn
Short-term assets $2.3bnLonger-term assets $271m
What it owes, and who funded it · $2.6bn
Short-term liabilities $141mLonger-term liabilities $767mShareholders' equity $1.6bn
  • Short-term assets cover short-term liabilities $2.3bn of assets due within a year against $141m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.3bn short-term assets against $767m of longer-dated liabilities.
  • More cash than debt $192m of cash against $587m of debt.
  • Debt below 40% of shareholders' equity Debt is 36% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$375m of operating cash flow against $587m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Crispr Therapeutics AG's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+10.0%
year over year
R&D spending
1156.6%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CRSP ABEO JANX STOK GLUE TNXP Median
Revenue, last 12 months $25m $26m $24m $28m $29m $29m $56m
Revenue growth, last 12 months −34.3% −87.7% >999% −86.2% −83.9% 196.0% 12.6%
Revenue growth, 3-year average −47.1% 212.0% 45.7% 46.1% — — 13.7%
Revenue growth, latest quarter >999% >999% >999% −32.5% −61.3% 577.9% 10.2%
Gross margin — 67.1% — — — 83.8% 82.9%
Operating margin <−999% −327.6% −598.1% −809.7% −633.0% −568.4% −189.4%
Operating margin, 3-year average <−999% <−999% <−999% −515.1% <−999% −881.2% −363.5%
Net margin <−999% −246.4% −427.5% −753.6% −560.8% −548.6% −169.8%
Cash from operations / revenue <−999% −299.5% −171.9% −645.2% −83.8% −525.7% −168.0%
Free-cash-flow margin <−999% −319.5% −174.7% −654.9% −111.7% −543.3% −162.4%
Free-cash-flow margin, 3-year average −793.9% <−999% <−999% −385.4% −424.9% −605.0% −310.0%
Stock pay / revenue 276.8% 45.4% 153.7% 135.7% 71.7% 27.3% 20.0%
Change in share count 10.0% 36.6% 6.2% 7.1% 11.9% — 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -34.3% 12.6% 134 of 172
Change in growth rate Growth +30.5pp -0.1pp 33 of 172
Operating margin Profitability -2114.8% -189.4% 148 of 175
Net margin Profitability -1812.1% -157.3% 149 of 180
Free-cash-flow margin Cash generation -1496.6% -145.4% 147 of 176
Stock pay as % of revenue Cash generation 276.8% 19.2% 156 of 179
Long-term debt as % of assets Balance sheet 23.0% 20.6% 45 of 78
Change in share count Balance sheet 10.0% 7.9% 91 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Grant $3.5M 100.0% ▲ 51.7%
Collaboration Revenue $0 0.0% ▼ 100.0%

From Crispr Therapeutics AG's 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$4.2B
Institutions reporting
516
Shares held vs prior quarter
▼ 1.2%
Positions opened / closed
72 / 48

Top buyers and sellers, Q2 2026: 228 institutions bought and 187 sold ; the biggest buyer was D. E. Shaw & Co., Inc (+894K shares) and the biggest seller ARK Investment Management LLC (−1.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
ARK Investment Management LLC $516M 9.5M 12.4% ▼ 16.4%
Blackrock, Inc. $455M 8.3M 10.9% ▲ 8.7%
Orbis Allan Gray Ltd $297M 5.4M 7.1% ▼ 10.8%
Capital World Investors $259M 4.7M 6.2% ▲ 0.5%
State Street Corp $236M 4.3M 5.7% ▲ 8.5%
Gsk PLC $176M 3.2M 4.2% 0.0%
Geode Capital Management, LLC $137M 2.5M 3.3% ▲ 5.6%
T. Rowe Price Investment Management, Inc. $112M 2.1M 2.7% ▼ 30.5%
Sr One Capital Management, LP $111M 2.0M 2.7% 0.0%
Two Sigma Investments, LP $108M 2.0M 2.6% ▲ 34.1%
FMR LLC $104M 1.9M 2.5% ▼ 2.4%
Sumitomo Mitsui Trust Group, Inc. $93.8M 1.7M 2.3% ▼ 7.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Crispr Therapeutics AG's complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $17.9M 30 trades by 6 insiders · 62% under pre-set plans
Net ▼ $17.9M net selling
Insider Date Trade Shares Price Value
Kulkarni Samarth Chief Executive Officer October 19, 2026 Sell 47,837 $49.78 $2.4M
Kulkarni Samarth Chief Executive Officer October 14, 2026 Sell 4,098 $49.26 $201,867
Kasinger James R. General Counsel and Secretary October 14, 2026 Sell 1,040 $49.26 $51,230
George Simeon Director October 14, 2026 Sell pre-set plan 14,514 $49.63 $720,373
Kasinger James R. General Counsel and Secretary October 6, 2026 Sell pre-set plan 1,990 $60.04 $119,481
Kasinger James R. General Counsel and Secretary September 22, 2026 Sell pre-set plan 10,400 $60.24 $626,496
Behbahani Ali Director September 17, 2026 Sell 13,679 $57.09 $780,934
Patel Naimish Chief Medical Officer May 29, 2026 Sell 3,786 $55.62 $210,577
Prasad Raju Chief Financial Officer March 23, 2026 Sell 3,708 $46.78 $173,460
Kulkarni Samarth Chief Executive Officer March 23, 2026 Sell 10,020 $46.78 $468,736
Kasinger James R. General Counsel and Secretary March 23, 2026 Sell 3,182 $46.78 $148,854
Kulkarni Samarth Chief Executive Officer March 16, 2026 Sell 10,349 $48.26 $499,443

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

No trades in Crispr Therapeutics AG disclosed in the last 12 months; 3 earlier trades on record.

  • Thomas R. Suozzi(D-NY 3):Sale (full), $50,001 - $100,000, traded September 20, 2021, filed October 5, 2021
  • Thomas R. Suozzi(D-NY 3):Purchase, $50,001 - $100,000, traded June 3, 2021, filed September 23, 2021
  • Marjorie Taylor Greene(R-GA 14):Purchase, $1,001 - $15,000, traded January 21, 2021, filed February 19, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 11, 2027 estimated from the company's past filing pattern, not announced

  • November 2, 2026
  • August 3, 2026
  • May 4, 2026
  • February 12, 2026
  • November 10, 2025
  • August 4, 2025

Recent SEC filings

Data status

When each part of this page on Crispr Therapeutics AG was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Crispr Therapeutics AG in brief

What does Crispr Therapeutics AG do?
Crispr Therapeutics AG is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Crispr Therapeutics AG's stock ticker?
Crispr Therapeutics AG trades under the ticker CRSP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Crispr Therapeutics AG's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Crispr Therapeutics AG reported revenue of $25.2M, 34.3% lower than a year earlier, according to its SEC filings.
What is Crispr Therapeutics AG's free cash flow?
Crispr Therapeutics AG's free-cash-flow margin is -1496.6% of revenue over the trailing twelve months, ranking 147 of the 176 biotechnology companies we cover.
Who are Crispr Therapeutics AG's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are ARK Investment Management LLC, Blackrock, Inc. and Orbis Allan Gray Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Crispr Therapeutics AG's market cap?
On November 2, 2026, Crispr Therapeutics AG's market capitalisation was about $4.8B and net debt of $408M. Market figures come from third-party market data and may be delayed.
How much debt does Crispr Therapeutics AG have?
Crispr Therapeutics AG's debt-to-equity ratio is 35.6%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Crispr Therapeutics AG's competitors?
In our Biotechnology peer group, the companies closest to Crispr Therapeutics AG are Abeona Therapeutics Inc., Janux Therapeutics, Inc., Stoke Therapeutics, Inc., Monte Rosa Therapeutics, Inc. and Tonix Pharmaceuticals Holding Corp. The side-by-side comparison below sets their revenue, margins and growth against Crispr Therapeutics AG's.
Are insiders buying or selling Crispr Therapeutics AG stock?
Over the last 12 months, Crispr Therapeutics AG's directors and officers reported 0 open-market purchases and 30 sales on Form 4. The insider trading page charts every trade.
When is Crispr Therapeutics AG's next earnings date?
Around February 11, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Crispr Therapeutics AG announces its own schedule.